Today: 30 June 2026
Lumentum stock jumps 10% as a new 2x ETF debuts and earnings loom
27 January 2026
1 min read

Lumentum stock jumps 10% as a new 2x ETF debuts and earnings loom

New York, Jan 27, 2026, 15:04 EST — Regular session

Lumentum Holdings Inc (LITE) shares surged 10.4%, hitting $367.04 in Tuesday afternoon trading, after peaking at an intraday high of $373.72. About 2.8 million shares changed hands.

This move is significant as Lumentum has turned into a popular pick for bets on faster connections within cloud data centers, where spending shifts have driven stock swings throughout the supply chain. The company produces optical and photonic components for cloud and communications networks and also sells lasers to industrial sectors.

Tradr ETFs unveiled a single-stock leveraged ETF linked to Lumentum, designed to deliver twice the stock’s daily price movement rather than its long-term gains. “We are excited to finally give traders high conviction tools,” said Matt Markiewicz, Tradr’s head of product and capital markets. He stressed these funds are built for short-term trading and reset daily. Nasdaq

The bid didn’t just lift Lumentum. Coherent jumped 6.9%, Ciena climbed 5.8%, and Applied Optoelectronics surged 8.2%.

The broader market climbed as well, with the Invesco QQQ Trust gaining roughly 0.9% and the SPDR S&P 500 ETF rising around 0.5%.

Investors are focused on whether the optical rally can hold up when results and guidance hit. For Lumentum, it often boils down to management’s take on cloud and networking demand, plus how solid the quarter appears — shipments, pricing, and the typical timing back-and-forth.

The new ETF could keep trading volume high for now. It offers leverage without the need for margin or options, yet it has the potential to turn an otherwise calm session into a volatile one.

However, after a double-digit surge, the situation is fragile. Should the next update disappoint or if risk appetite fades, those gains in high-beta stocks could evaporate fast.

Lumentum will release its fiscal second-quarter results after the market closes on Feb. 3, followed by a webcast at 5:00 p.m. ET, the company announced. Investors are watching that report and the accompanying outlook commentary as the next key drivers for the stock.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom
Previous Story

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom

National Grid share price holds near fresh 52-week high as €650m bond sale puts funding back in focus
Next Story

National Grid share price holds near fresh 52-week high as €650m bond sale puts funding back in focus

Go toTop